Your browser doesn't support javascript.
loading
Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes.
Sop, Joel; Traut, Caroline C; Dykema, Arbor G; Hunt, Joanne H; Beckey, Tyler P; Basseth, Christie R; Antar, Annukka A R; Laeyendecker, Oliver; Smith, Kellie N; Blankson, Joel N.
Afiliación
  • Sop J; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
  • Traut CC; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
  • Dykema AG; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Hunt JH; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Baltimore, MD, USA.
  • Beckey TP; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
  • Basseth CR; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
  • Antar AAR; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
  • Laeyendecker O; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Baltimore, MD, USA.
  • Smith KN; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. Electronic address: ksmit228@jhmi.edu.
  • Blankson JN; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA. Electronic address: jblanks@jhmi.edu.
Cell Rep Med ; 5(3): 101442, 2024 Mar 19.
Article en En | MEDLINE | ID: mdl-38423018
ABSTRACT
Bivalent COVID vaccines containing mRNA for ancestral and Omicron BA.5 spike proteins do not induce stronger T cell responses to Omicron BA.5 spike proteins than monovalent vaccines that contain only ancestral spike mRNA. The reasons for this finding have not been elucidated. Here, we show that healthy donors (HDs) and people living with HIV (PLWH) on antiretroviral therapy mostly target T cell epitopes that are not affected by BA.5 mutations. We use the functional expansion of specific T cells (FEST) assay to determine the percentage of CD4+ T cells that cross-recognize both spike proteins and those that are monoreactive for each protein. We show a predominance of cross-reactive CD4+ T cells; less than 10% percent of spike-specific CD4+ T cell receptors were BA.5 monoreactive in most HDs and PLWH. Our data suggest that the current bivalent vaccines do not induce robust BA.5-monoreactive T cell responses.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Vacunas de ARNm Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Vacunas de ARNm Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos